1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

15 Sep 2020
Admin
News Article

Novartis Phase Iiib Exchange & Expand Trials Show Mayzent To Be Safe Treatment Option In Patients With Spms

Novartis Announced That Mayzent (Siponimod) Analyses From The Phase Iiib Exchange And Expand Trials Showed Mayzent To Be A Safe Treatment Option That Has Benefits In Cognitive Performance And Reduces The Risk Of Disability Progression In Patients With Progressing Ms1-3. The Data Were Presented At The Msvirtual2020: 8Th Joint Actrims-Ectrims Meeting That Is Taking Place September 11&Ndash;13, 2020.&Ldquo;One Of The Biggest Goals For People Living With Ms Is To Be Able To Live Their Lives Independently For As Long As Possible," Said Norman Putzki, Md, Global Head Of Development, Neuroscience. &Ldquo;The Data Presented Today Reinforces That Through Its Beneficial Effects On Cognitive Performance And Delaying Disability Progression, And As An Appropriate Option For Patients To Safely Switch To/From Other Treatments, Mayzent Offers Hope For People Looking To Achieve This Important Goal.&Rdquo;The Exchange Study Is A Phase Iiib Prospective, Six-Month Open-Label Study Evaluating The Safety And Tolerability Of Conversion To Mayzent From Other Disease-Modifying Therapies (Dmts) In Patients With Relapsing Multiple Sclerosis (Rms), Including Active Secondary Progressive Multiple Sclerosis (Spms). The Interim Analysis Included 112 Patients From 42 Centers In The Us Who Were Eligible For The Safety Analysis.The Expand Study Is A Randomized, Double-Blind, Placebo-Controlled Phase Iii Study, Comparing The Efficacy And Safety Of Mayzent Versus Placebo In Patients With Spms With Varying Levels Of Disability. The Post Hoc Expand Analysis Found That In Patients With Active Disease, An Increased Chance For Clinically Relevant Improvement Was Observed And Patients With Active Spms Early And Continuously Treated With Mayzent Experienced Lower Risk Of Disability Progression And Cognitive Decline Than Patients Who Delayed Mayzent Treatment.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!